116 related articles for article (PubMed ID: 23395660)
21. SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.
Ramtohul YK; Black C; Chan CC; Crane S; Guay J; Guiral S; Huang Z; Oballa R; Xu LJ; Zhang L; Li CS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1593-7. PubMed ID: 20137926
[TBL] [Abstract][Full Text] [Related]
22. Discovery of novel SCD1 inhibitors: 5-alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4'-piperidine] analogs.
Uto Y; Ueno Y; Kiyotsuka Y; Miyazawa Y; Kurata H; Ogata T; Takagi T; Wakimoto S; Ohsumi J
Eur J Med Chem; 2011 May; 46(5):1892-6. PubMed ID: 21356569
[TBL] [Abstract][Full Text] [Related]
23. High-throughput scintillation proximity assay for stearoyl-CoA desaturase-1.
Tawa P; Falgueyret JP; Guiral S; Isabel E; Powell DA; Zuck P; Skorey K
J Biomol Screen; 2011 Jun; 16(5):506-17. PubMed ID: 21406617
[TBL] [Abstract][Full Text] [Related]
24. Stearoyl-CoA desaturase inhibitors: update on patented compounds.
Liu G
Expert Opin Ther Pat; 2009 Sep; 19(9):1169-91. PubMed ID: 19691439
[TBL] [Abstract][Full Text] [Related]
25. Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors.
Zhao H; Serby MD; Smith HT; Cao N; Suhar TS; Surowy TK; Camp HS; Collins CA; Sham HL; Liu G
Bioorg Med Chem Lett; 2007 Jun; 17(12):3388-91. PubMed ID: 17434733
[TBL] [Abstract][Full Text] [Related]
26. Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors.
Uto Y
Chem Phys Lipids; 2016 May; 197():3-12. PubMed ID: 26344107
[TBL] [Abstract][Full Text] [Related]
27. Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
Iida T; Ubukata M; Mitani I; Nakagawa Y; Maeda K; Imai H; Ogoshi Y; Hotta T; Sakata S; Sano R; Morinaga H; Negoro T; Oshida S; Tanaka M; Inaba T
Eur J Med Chem; 2018 Oct; 158():832-852. PubMed ID: 30248655
[TBL] [Abstract][Full Text] [Related]
28. Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity.
Dillon R; Greig MJ; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):99-104. PubMed ID: 18790132
[TBL] [Abstract][Full Text] [Related]
29. Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.
Li CS; Belair L; Guay J; Murgasva R; Sturkenboom W; Ramtohul YK; Zhang L; Huang Z
Bioorg Med Chem Lett; 2009 Sep; 19(17):5214-7. PubMed ID: 19632834
[TBL] [Abstract][Full Text] [Related]
30. Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.
Lachance N; Gareau Y; Guiral S; Huang Z; Isabel E; Leclerc JP; Léger S; Martins E; Nadeau C; Oballa RM; Ouellet SG; Powell DA; Ramtohul YK; Tranmer GK; Trinh T; Wang H; Zhang L
Bioorg Med Chem Lett; 2012 Jan; 22(2):980-4. PubMed ID: 22209206
[TBL] [Abstract][Full Text] [Related]
31. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.
Uto Y; Ogata T; Harada J; Kiyotsuka Y; Ueno Y; Miyazawa Y; Kurata H; Deguchi T; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Abe M; Kurikawa N; Kawamura S; Yamato M; Osumi J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4151-8. PubMed ID: 19540759
[TBL] [Abstract][Full Text] [Related]
32. Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy.
Roongta UV; Pabalan JG; Wang X; Ryseck RP; Fargnoli J; Henley BJ; Yang WP; Zhu J; Madireddi MT; Lawrence RM; Wong TW; Rupnow BA
Mol Cancer Res; 2011 Nov; 9(11):1551-61. PubMed ID: 21954435
[TBL] [Abstract][Full Text] [Related]
33. Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors.
Isabel E; Powell DA; Black WC; Chan CC; Crane S; Gordon R; Guay J; Guiral S; Huang Z; Robichaud J; Skorey K; Tawa P; Xu L; Zhang L; Oballa R
Bioorg Med Chem Lett; 2011 Jan; 21(1):479-83. PubMed ID: 21074991
[TBL] [Abstract][Full Text] [Related]
34. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase.
Dobrzyn P; Dobrzyn A
Expert Opin Ther Pat; 2010 Jun; 20(6):849-53. PubMed ID: 20205608
[TBL] [Abstract][Full Text] [Related]
35. Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.
Powell DA; Black WC; Bleasby K; Chan CC; Deschenes D; Gagnon M; Gordon R; Guay J; Guiral S; Hafey MJ; Huang Z; Isabel E; Leblanc Y; Styhler A; Xu LJ; Zhang L; Oballa RM
Bioorg Med Chem Lett; 2011 Dec; 21(24):7281-6. PubMed ID: 22047692
[TBL] [Abstract][Full Text] [Related]
36. Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.
Liu G; Lynch JK; Freeman J; Liu B; Xin Z; Zhao H; Serby MD; Kym PR; Suhar TS; Smith HT; Cao N; Yang R; Janis RS; Krauser JA; Cepa SP; Beno DW; Sham HL; Collins CA; Surowy TK; Camp HS
J Med Chem; 2007 Jun; 50(13):3086-100. PubMed ID: 17530838
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
Issandou M; Bouillot A; Brusq JM; Forest MC; Grillot D; Guillard R; Martin S; Michiels C; Sulpice T; Daugan A
Eur J Pharmacol; 2009 Sep; 618(1-3):28-36. PubMed ID: 19616540
[TBL] [Abstract][Full Text] [Related]
38. Sequential Dynamics of Stearoyl-CoA Desaturase-1(SCD1)/Ligand Binding and Unbinding Mechanism: A Computational Study.
Petroff AB; Weir RL; Yates CR; Ng JD; Baudry J
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680068
[TBL] [Abstract][Full Text] [Related]
39. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.
Uto Y; Ogata T; Kiyotsuka Y; Miyazawa Y; Ueno Y; Kurata H; Deguchi T; Yamada M; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Konishi M; Kurikawa N; Kono K; Osumi J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4159-66. PubMed ID: 19541482
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of stearoyl-CoA desaturase1 activates AMPK and exhibits beneficial lipid metabolic effects in vitro.
Kim E; Lee JH; Ntambi JM; Hyun CK
Eur J Pharmacol; 2011 Dec; 672(1-3):38-44. PubMed ID: 21970804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
